Hong Kong: Becoming a Biotech Funding Hub
2018 marked a significant milestone in Hong Kong’s journey towards creating a vibrant biotech market for investors which allows Asian innovation to receive the funding it needs to progress. It…
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Oncology, Cardiovascular & Metabolic Disease and Respiratory. We are also selectively active in the areas of autoimmunity, neuroscience and infection. Its presence in Hong Kong – in the name of AstraZeneca Hong Kong – can be traced back to 1999 when AstraZeneca was formed following a merger of Astra AB of Sweden and Zeneca Group PLC of the UK. Both companies were established in Hong Kong in the 1970s.
AstraZeneca Hong Kong oversees both the Hong Kong and Macau markets and attaches a strong importance to them. Since our establishment, we have been focusing on identifying and bringing in the latest medical solutions as well as seeking ongoing business development. Over the years, we have been continually expanding our business in order to meet the growing demand of the markets.
Contact
Address: Unit 1-3, 11/F, 18 King Wah Road, North Point
Tel: +(852) 2420 7388
Website: https://www.astrazeneca.com/country-sites/hong-kong.html
2018 marked a significant milestone in Hong Kong’s journey towards creating a vibrant biotech market for investors which allows Asian innovation to receive the funding it needs to progress. It…
Insighta, formed this year as a 50/50 joint venture between genomics-focused outfit Prenetics and one of the city’s most feted scientific sons, Professor Dennis Lo, is aiming to change the…
Almost a decade on from the establishment of a Phase I clinical trial centre in Hong Kong, the city continues to pursue a stronger positioning within the global clinical research…
Albert Wong of the Hong Kong Science and Technology Parks Corporation (HKSTP) outlines how Hong Kong has developed as an innovation hub, building on its established areas of finance and…
Novartis, one of the world’s largest biopharma companies, has secured approval and market access for two of its most advanced cell and gene treatments in Hong Kong. The firm’s territory…
Generative Artificial Intelligence (AI) has grabbed a lot of media attention in recent months following the launch of chatbot ChatGPT, but the pharmaceutical industry has long been trying – and…
One of Asia’s most pre-eminent oncologists, Professor Tony Mok is perhaps best known for discovering the EGFR mutation gene and subsequently developing a targeted therapy that is more precise and…
Established in 2017 as a spin-off from Lee’s Pharmaceutical, Zhaoke Ophthalmology is aiming to be a global player in the ophthalmology field, building on its strong footprint in China and…
Serial entrepreneur Danny Yeung highlights the work of his Hong Kong-based genomics-driven firm Prenetics in prevention, early detection and targeted therapy. Having recently announced a USD 200 million joint venture…
Since first allowing pre-revenue biotechs to list in 2018, the Hong Kong stock exchange has welcomed 59 such companies and is now a leading vehicle for allowing Chinese biopharma to…
The Hong Kong Association of the Pharmaceutical Industry (HKAPI) represents the interests of the global R&D-based biopharmaceutical industry in Hong Kong and Macau. Senior Executive Director Sabrina Chan outlines the…
AstraZeneca, the largest overseas pharmaceutical company in mainland China by sales, is also the market leader in Hong Kong and Macau, a territory overseen by General Manager Shan Wu. She…
See our Cookie Privacy Policy Here
